author-photo

William Accomando

Brown University

25

Papers

2299

Citations

Citation Trend

Filter By

Papers (21) Sort By

Journal Conference Others

Immune modulation after Toca 511 and Toca FC treatment of colorectal cancer patients.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
PD-L1 checkpoint blockade delivered by retroviral replicating vector confers anti-tumor efficacy in murine tumor models

2019 Oncotarget
Show All
- Source
- Cite
- Save
Citations (7)
Abstract A085: Durable responses observed in recurrent high-grade glioma (rHGG) with Toca 511 and Toca FC treatment

2018 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (0)
Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC

2018 Neuro-oncology
Show All
- Source
- Cite
- Save
Citations (81)
25 Durable complete responses observed in patients with recurrent high grade glioma treated with Toca 511 & Toca FC

2018 Canadian Journal of Neurological Sciences
Show All
- Source
- Cite
- Save
Citations (0)
Abstract B010: Antitumor cellular immune response elicited by Toca 511 and Toca FC therapy in preclinical and clinical studies

2018 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (0)
Treatment of recurrent hgg patients with the retroviral replicating vector Toca 511 and Toca FC gives durable responses and survival lasting 3 years or longer: Immune mechanisms and molecular analyses of tumors

2018
Show All
- Source
- Cite
- Save
Citations (0)
Toca 511 & Toca FC: Evaluation of Durable Response Rate in the Post-Resection Setting and Association with Survival in Patients with Recurrent High Grade Glioma (S23.006)

2018 Neurology
Show All
- Source
- Cite
- Save
Citations (0)
Durable responses observed in recurrent high-grade glioma (rHGG) with Toca 511 and Toca FC treatment

2018
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 5630: Immune profile of tumor microenvironment helps predict response in patients treated with an investigational immunotherapeutic consisting of a retroviral replicating vector (Toca 511) and an extended-release formulation of 5-fluorocytosine (Toca FC)

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)